|
Volumn 34, Issue 5, 2016, Pages 458-461
|
No longer going to waste
a
a
NONE
(United States)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ACE 2454;
ACTIVIN RECEPTOR;
BIMAGRUMAB;
DOMAGROZUMAB;
LANDOGROZUMAB;
MYOSTATIN;
ORPHAN DRUG;
RAMATERCEPT;
SELECTIVE ANDROGEN RECEPTOR MODULATOR;
SMAD PROTEIN;
TREVOGRUMAB;
UNCLASSIFIED DRUG;
BLOCKING ANTIBODY;
MONOCLONAL ANTIBODY;
ARTICLE;
CACHEXIA;
CELL SURFACE;
CENTRAL NERVOUS SYSTEM;
DRUG INDUSTRY;
DRUG PROGRAM;
END STAGE RENAL DISEASE;
EXTRACELLULAR MATRIX;
HUMAN;
LEAN BODY WEIGHT;
MUSCLE ATROPHY;
MUSCLE MASS;
PHARMACEUTICAL CARE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
RNA SPLICING;
SARCOPENIA;
SKELETAL MUSCLE;
DRUG APPROVAL;
DRUG MANUFACTURE;
EUROPE;
EVIDENCE BASED MEDICINE;
MYOSITIS;
TREATMENT OUTCOME;
UNITED STATES;
ANTIBODIES, BLOCKING;
ANTIBODIES, MONOCLONAL;
DRUG APPROVAL;
EUROPE;
EVIDENCE-BASED MEDICINE;
HUMANS;
MUSCULAR ATROPHY;
MYOSITIS;
ORPHAN DRUG PRODUCTION;
TREATMENT OUTCOME;
UNITED STATES;
|
EID: 84967156225
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt.3557 Document Type: Article |
Times cited : (47)
|
References (12)
|